FDA Drug recall D-1133-2017
Timolol-Brimonidine-Dorzolamide-Latanoprost (0.5/0.15/2/0.005)% Ophthalmic Drops, Sterile 5ml Bottle, Compounded for a licensed professiona…
- FDA Drug
- Class II
- terminated
- Published 2017-09-13
On 2017-09-13 the FDA classified a Class II recall of Timolol-Brimonidine-Dorzolamide-Latanoprost (0.5/0.15/2/0.005)% Ophthalmic Drops, Sterile 5ml Bottle, Compounded for a licensed professiona… by Imprimisrx Ca, citing incorrect/Undeclared Excipient; non-pharmaceutical grade PEG 40 Castor Oil was used due to a mislabeling by the supplier.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1133-2017 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2017-06-23 |
| Published | 2017-09-13 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Imprimisrx Ca |
| Distribution | US |
Product
Timolol-Brimonidine-Dorzolamide-Latanoprost (0.5/0.15/2/0.005)% Ophthalmic Drops, Sterile 5ml Bottle, Compounded for a licensed professional or patient use, imprimisRx, Irvine, CA
Reason
Incorrect/Undeclared Excipient; non-pharmaceutical grade PEG 40 Castor Oil was used due to a mislabeling by the supplier
Identifiers
| code_info | 05092017@2B, 11/5/2017 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1133-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.